Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients

被引：58

作者：

Brown, RE ^{[1
]}

机构：

[1] Geisinger Med Ctr, Danville, PA 17822 USA

来源：

EXPERT REVIEW OF PROTEOMICS | 2005年 / 2卷 / 03期

关键词：

morphoproteomics; personalized medicine; proteasome inhibitors; rapamycin; signal transduction;

D O I：

10.1586/14789450.2.3.337

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Morphoproteomics combines the disciplines of histopathology, molecular biology and protein chemistry to paint a portrait of the protein circuitry in diseased cells for the purpose of uncovering molecular targets amenable to specific intervention, thereby customizing therapy for individual patients. This review considers the clinical application of morphoproteomics in malignant cells in the context of currently available pharmaceutical agents and discusses opportunities for combinatorial approaches that involve one or more small molecule inhibitors and single-agent chemotherapy with relatively low toxicity profiles. Future directions that involve focusing on points of convergence in signal transduction pathways and which integrate morphoproteomic with genomic and pharmacoproteomic and protein-function microarray data are offered.

引用

页码：337 / 348

页数：12

共 85 条

[11]

Brown RE, 2000, MED PEDIATR ONCOL, V34, P311, DOI 10.1002/(SICI)1096-911X(200004)34:4<311::AID-MPO26>3.0.CO

[12]

2-Z

[13]

Brown RE, 2001, NEW ENGL J MED, V345, P1503

[14] New targets for therapy in breast cancer - Mammalian target of rapamycin (mTOR) antagonists [J].